SCHEMBL10176890

SCHEMBL10176890

Cc1ccc(-c2ccc3c(c2)nc2n3CCN(C3CCC3)CC2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.42
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 6/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
MCL1 Q07820 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP11B2 P19099 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176638 0.92 ALDH1A1 (0.36) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL10176938 0.88 MAPT (0.43) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7889358 0.87 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL421308 0.85 PDE4A (0.41) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL10176666 0.84 MAPT (0.47) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL10176895 0.84 MAPT (0.43) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7885644 0.84 MAPT (0.49) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7879894 0.83 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL10176894 0.83 HRH3 (0.45) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL16297759 0.83 MAPT (0.42) MAPTALDH1A1KDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 US disclosed
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 MAPT 738/4885ALDH1A1 2598/4885KDM4E 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.